Frozen in Shipping: What the Insulin and Sarclisa Recalls Teach About Cold-Chain Control

In late September 2026, two separate recalls moved through Canada's drug supply for the same reason. Units of insulin and units of the cancer therapy Sarclisa may have been frozen in transit, and both were classed as Type I recalls, the most serious category Health Canada uses. Neither product failed in the factory. Each one was made correctly, released correctly, and then compromised somewhere between the loading dock and the pharmacy fridge. For distributors, importers and licence holders, that is the uncomfortable lesson: your quality system does not end when the batch is released.

Executive summary

This article explains what the Sanofi insulin and Sarclisa recalls reveal about cold-chain control in Canada, why a freeze is a genuine drug-quality failure, and how to build a distribution and temperature-excursion programme that holds up to a Health Canada inspection. It is written for distributors, importers, drug establishment licence holders and quality teams responsible for storage and transportation. The recalls were reported in Health Canada's October 2026 Health Product InfoWatch.

What happened: two Type I recalls, one root cause

Sanofi-Aventis Canada recalled certain insulin pens and cartridges, and separately recalled a limited number of Sarclisa vials, because the products may have been frozen during shipping. Both were classed Type I. Insulin and this biologic can lose effectiveness if frozen, so the units were pulled even though only a small share of each shipment was affected.

The insulin recall covered selected lots across several products, including Admelog, Apidra, Lantus, Toujeo and Trurapi presentations. Only a limited number of units in each lot were recalled, about 1,043 units in total, described as less than one percent of the units distributed. The affected shipments reached roughly 80 pharmacies, clinics and hospitals across Canada in July and August 2026. Unopened insulin should be kept refrigerated at 2°C to 8°C and should never be frozen.

The Sarclisa recall was far smaller in scope, nine vials from a single lot distributed to three locations in Nova Scotia, again because the units may have been frozen during shipment. Sarclisa (isatuximab) is a monoclonal antibody, and like insulin it is a cold-chain product whose quality can be harmed by freezing. The recall was dated 23 September 2026.

Why a freeze is a drug-quality failure, not a shipping nuisance

A temperature excursion below the labelled range is a quality defect because it can change the product. Freezing can denature proteins, break emulsions, crack containers and alter the dose a patient actually receives. For insulin and antibody therapies, a freeze that the eye cannot always see may still reduce potency. That is why Health Canada treats a possible freeze as a recallable event.

Insulin is a protein. When it freezes, the structure can change and the product may no longer control blood sugar reliably, which can lead to hyperglycaemia. Biologics such as monoclonal antibodies are even more sensitive, because aggregation caused by freezing can affect both efficacy and safety. The key point for quality teams is that you often cannot confirm a product is still good after a freeze, so the conservative and compliant response is to quarantine and investigate.

The regulatory basis in Canada

Storage and transportation of drugs sit squarely inside good manufacturing practices. Health Canada's Guidelines for temperature control of drug products during storage and transportation, GUI-0069, set out the expectation that drugs are kept within their labelled conditions from manufacture to the point of sale. The underlying GMP requirements appear in Part C, Division 2 of the Food and Drug Regulations, and are explained in the Good manufacturing practices guide, GUI-0001. Distributors and importers who hold a drug establishment licence are accountable for these controls across their lanes.

Where cold-chain control breaks down

Most freezing excursions trace back to a few predictable gaps. The product is correct, but the packout, the lane, the monitoring or the handoff is not. Mapping these failure points is the first step to preventing the next recall.

• Unqualified shipping configurations: a box, gel pack or insulation set never validated for the season, duration or route it is actually used on.
• Winter lanes without a cold-weather packout: summer validation does not prove a shipper will hold 2°C to 8°C through a prairie cold snap.
• No temperature monitoring: shipments sent without a data logger or indicator, so a freeze arrives invisible.
• Weak handoffs: product left on a loading dock, in an unheated vehicle or in a courier depot over a weekend.
• No receiving check: warehouses that book product into saleable stock before reading the monitor or confirming the excursion status.
• Unclear accountability: manufacturer, third-party logistics provider, carrier and importer each assume another party owns the cold chain.

How to investigate a temperature excursion

When a logger shows a freeze or a near-freeze, the quality unit runs a documented investigation before the product moves. The goal is a defensible decision on product disposition, a clear root cause, and corrective actions that stop the excursion from repeating. Treat it like any deviation or out-of-specification event.

1. Quarantine immediately. Place the affected units on hold and do not release them to saleable stock.
2. Secure the data. Download the temperature logger, record the duration and depth of the excursion, and keep the raw file.
3. Assess against stability data. Compare the excursion to the product's known temperature limits and any manufacturer freeze guidance.
4. Decide disposition. The quality unit, not sales or logistics, decides whether to release, return or destroy the product.
5. Find the root cause. Identify whether the packout, lane, season, carrier or handoff failed, using the real shipping record.
6. Implement CAPA. Requalify the shipper, change the packout, add monitoring or retrain the carrier, then verify the fix works.
7. Report if required. Notify Health Canada and initiate a recall where the risk to patients meets the reporting threshold.

Building a cold-chain compliance programme

A reliable cold chain is a programme, not a single SOP. It connects qualification, monitoring, people and documentation so that every temperature-sensitive shipment is controlled and provable. The table below shows the core elements Health Canada expects to see.

Cold-chain compliance checklist

Use this checklist to gauge whether your distribution controls would survive an inspection or a cold-weather shipping season.

• Every temperature-sensitive product has defined labelled storage conditions on file.
• Shipping configurations are validated for each product, season, duration and route in use.
• Winter and summer packouts are separately qualified, not assumed interchangeable.
• Data loggers or indicators travel with shipments that require them.
• Receiving staff read monitors and confirm excursion status before product is made saleable.
• A written temperature-excursion investigation SOP defines quarantine, assessment and disposition.
• The quality unit, not logistics, owns final product disposition decisions.
• Supplier, third-party logistics and carrier responsibilities are defined in written agreements.
• Warehouse storage areas are mapped and monitored, with alarms and backup.
• A mock recall has been run in the last 12 months and found affected units quickly.

Common mistakes

• Validating a shipper once and assuming it works in every season and on every lane.
• Treating a logger alarm as a logistics problem instead of a quality deviation.
• Letting receiving staff release cold-chain product to saleable stock before checking the monitor.
• Relying on the carrier to own the cold chain without a written agreement or audit.
• Keeping no stability or freeze-sensitivity data to support a disposition decision.
• Finding the product but not finding the root cause, so the same excursion repeats.

Frequently asked questions

What is a Type I recall in Canada?

A Type I recall is Health Canada's most serious recall class. It applies where there is a reasonable probability that using or being exposed to the product will cause serious adverse health consequences or death. Both the insulin and Sarclisa recalls were Type I because compromised product could put patients at real risk.

Can frozen insulin still be used?

No. Insulin that may have been frozen should not be used, because freezing can reduce its effectiveness and lead to poor blood-sugar control. Health Canada's advice for the affected products was to stop using them, or any product you are unsure about, and to return them for a replacement.

Who is responsible for cold-chain compliance in Canada?

Everyone who holds the product is accountable within their part of the chain. Manufacturers, importers, distributors and drug establishment licence holders must keep drugs within labelled conditions during storage and transportation under GUI-0069 and Part C, Division 2 of the Food and Drug Regulations. Written agreements should assign specific duties to third-party logistics providers and carriers.

What does GUI-0069 require?

GUI-0069 sets Health Canada's expectations for temperature control of drug products during storage and transportation. In practice that means knowing each product's labelled conditions, qualifying storage areas and shipping configurations, monitoring temperature, investigating excursions, and keeping records that prove control from manufacture to sale.

When does a temperature excursion become a recall?

A temperature excursion becomes a recall when the quality unit concludes the product may be compromised and that distributed units pose a risk to patients. If affected stock has already shipped, the licence holder assesses the health risk and, where the threshold is met, initiates a recall and notifies Health Canada.

How can a distributor prepare for winter shipping?

Qualify a dedicated cold-weather packout, map the lanes most exposed to freezing, add temperature monitoring to at-risk shipments, and brief carriers on handling and handoff rules. Then run a mock excursion so staff know how to quarantine, investigate and decide disposition before the real cold snap arrives.

How MFLRC can help

MF License and Regulatory Consultants helps distributors, importers and licence holders turn cold-chain risk into a controlled, inspection-ready programme. We work the way a Health Canada inspector reads your file, from qualification evidence through to the excursion record that proves you acted.

• Good distribution practice and cold-chain gap assessments against GUI-0069.
• Shipper and lane qualification support, including winter packout strategy.
• SOP development for temperature-excursion investigation and product disposition.
• Supplier and carrier audits with clear accountability agreements.
• CAPA programme design so excursions are closed out and do not repeat.
• Mock recalls and recall-readiness reviews.

Shipping temperature-sensitive products? Book an MFLRC cold-chain gap assessment before an excursion becomes a recall.

Conclusion

The insulin and Sarclisa recalls are a reminder that drug quality can be lost after the batch is released. A freeze in transit is not a shipping inconvenience, it is a quality defect that can reach a patient. The licence holders that avoid the next Type I recall are the ones that qualify their shippers, monitor their lanes, read their loggers on receipt, and investigate every excursion with a written procedure. Cold-chain control is not optional, it is part of your GMP obligation.

Sources and references

• Health Canada, Health Product InfoWatch, October 2026.
• Health Canada, Recalls and Safety Alerts, Sanofi-Aventis Canada Inc. recalling certain insulin pens and cartridges.
• Health Canada, Recalls and Safety Alerts, Limited number of Sarclisa single-use vials may have been frozen during shipment.
• Health Canada, Guidelines for Temperature Control of Drug Products during Storage and Transportation (GUI-0069).
• Health Canada, Good manufacturing practices guide for drug products (GUI-0001).